Clinical Trials Directory

Trials / Completed

CompletedNCT01898910

Ganglionated Plexi Ablation vs Renal Denervation in Patients Undergoing Pulmonary Vein Isolation

Ganglionated Plexi Ablation vs Renal Denervation in Patients Undergoing Pulmonary Vein Isolation. A Randomized Comparison

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
80 (actual)
Sponsor
Meshalkin Research Institute of Pathology of Circulation · Network
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

The investigators have conducted a prospective, double-blind, randomized study to assess the comparative safety and efficacy of two different strategies, PVI plus Renal Denervation (RD) versus PVI plus GP ablation, in patients with atrial fibrillation. Results were assessed after follow-up of at least 1 year with the use of an implanted monitoring device (IMD).

Conditions

Interventions

TypeNameDescription
PROCEDUREPVI+renal denervationAfter AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done.
PROCEDUREPVI + GP ablationTo accomplish ganglionated plexi ablation, LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter high-frequency stimulation (HFS). Rectangular electrical stimuli were delivered at a frequency of 20-50 Hz, output amplitude 15 V and pulse duration of 10 ms, for 5 sec (Stimulator B-53, Biotok Inc, Russia).
DRUGOptimal medial therapy (OMT)Antiarrhythmic and antihypertensive therapy will be administered according to the guidelines

Timeline

Start date
2012-06-01
Primary completion
2013-06-01
Completion
2013-06-01
First posted
2013-07-15
Last updated
2013-07-15

Locations

1 site across 1 country: Russia

Source: ClinicalTrials.gov record NCT01898910. Inclusion in this directory is not an endorsement.